Recent legislative and regulatory actions across the United States are shaping the future of both medical cannabis and industrial hemp sectors. These developments include a gubernatorial veto in Virginia, new licensing pathways in California, and growing concerns regarding the integrity of the industrial hemp market in Colorado. These shifts in cannabis and hemp policy underscore the complex and evolving regulatory environment for businesses and stakeholders.
Legislative and Regulatory Developments
State-Level Policy Actions
Virginia Governor Abigail Spanberger (D) vetoed legislation intended to establish a framework for recreational cannabis sales. The veto followed lawmakers’ rejection of her proposed amendments, which included a six-month delay to market launch, increased taxation, and the introduction of new criminal penalties for cannabis consumers, according to a report by Marijuana Moment. This action highlights ongoing debates regarding market structure and regulatory oversight in states considering broader cannabis access.
In California, the Department of Cannabis Control is proposing emergency rules to facilitate state-licensed cannabis businesses in leveraging federal benefits following the Trump administration’s rescheduling decision. The proposed rules would allow entities holding existing medical and recreational licenses to secure a secondary license via a streamlined process, enabling the separation of operational segments. This aims to simplify compliance and access to federal programs for medical cannabis operators.
Louisiana lawmakers have advanced a bill to Governor Jeff Landry (R) that proposes penalties of up to one year in jail for individuals smoking marijuana within 2,000 feet of school properties, including college campuses. This legislative measure reflects a trend toward stricter enforcement of public consumption laws in certain jurisdictions.
New Jersey’s Assembly passed a bill to permit the sale of large-container hemp beverages and allow medical cannabis dispensaries to incorporate adult-use marijuana sales without requiring additional local approval. This move could expand market access for both hemp-derived products and medical cannabis businesses.
Federal Regulatory Landscape
The Drug Enforcement Administration (DEA) is proposing changes to its annual drug production quota setting process. Concurrently, the Substance Use and Mental Health Services Administration (SAMHSA) issued an advisory addressing cannabis use disorder, indicating a federal focus on public health aspects related to cannabis consumption.
Industrial Hemp and Market Integrity
The U.S. Army issued a warning to soldiers, reiterating the prohibition of cannabis use, which extends to common hemp items containing CBD such as vape juices, food, hair care products, oils, lotions, and other cosmetics. The warning cited potential risks to physical and mental readiness from all types of cannabinoids, underscoring the military’s strict stance on hemp-derived product consumption.
Concerns about market integrity within the industrial hemp sector were voiced by the deputy senior director of the Colorado Marijuana Enforcement Division. In a meeting with industry representatives, the official stated that the volume of chemically converted hemp being illicitly sold as marijuana is “larger than we can quantify” and would be startling to many, as reported by Marijuana Moment. This issue highlights challenges in distinguishing regulated cannabis products from unregulated hemp-derived alternatives.
Medical Cannabis Research and Business Performance
Scientific Findings and Public Health
A federally funded study, which analyzed claims data from 107.5 million commercially insured adults, reported an association between cannabis legalization and significant reductions in non-fatal opioid poisonings. The researchers suggested that greater access to cannabis may be associated with a reduction in opioid poisoning diagnoses in heavily impacted populations, indicating a potential for cannabis to be considered as a substitute for opioids in some contexts.
In scientific research, a review suggested that cannabidiol (CBD) may exhibit effects on antitumor pathways through multi-target and multi-pathway mechanisms. These mechanisms, as discussed in the review, include oxidative stress, mitochondrial dysfunction, endoplasmic reticulum stress, calcium homeostasis imbalance, and modulation of signaling networks, contributing to the growing body of research on cannabinoid pharmacology.
Industry Financial Reporting
In corporate news, SHF Holdings, Inc., operating as Safe Harbor Financial, reported quarterly revenue of US$2 million and a net loss of US$1.8 million. Federal officials initiated a lawsuit stating that TerrAscend erroneously received more than US$8 million in tax refunds. Separately, FundCanna secured a new senior credit facility of up to US$60 million, indicating continued investment activity in the sector.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
